Rilan: Understanding the Risks, Regulatory Actions, and Safer Alternatives for Children’s Sleep Products

What Is Rilan—and Why Was It Recalled?

Rilan was a line of infant sleep positioners manufactured by Harmony Baby Products, Inc., marketed between 2009 and 2012. These devices consisted of two firm foam wedges connected by a Velcro strap, designed to hold infants on their sides or backs during sleep. Sold under names including 'Rilan Side Sleeper' and 'Rilan Newborn Positioner,' they were widely distributed through major retailers including Babies "R" Us, Target, and Amazon. The CPSC issued a mandatory recall on June 13, 2012, after confirming that the product contributed to at least four infant deaths and multiple near-fatal incidents. According to CPSC Report No. 12-027, all four fatalities occurred in infants aged 1–4 months who were placed supine or side-lying in the device and subsequently rolled or shifted into positions that obstructed airways. Autopsy reports confirmed positional asphyxia as the cause of death in each case.

The Rilan positioner measured 22 inches long × 12 inches wide × 4 inches high at its tallest point. Its foam density was rated at 18 ILD (Indentation Load Deflection), meaning it offered minimal compressibility—firm enough to resist infant movement but not firm enough to prevent entrapment. Independent testing by the National Institute of Standards and Technology (NIST) found that when infants moved within the device, their heads could tilt forward more than 35 degrees—the threshold at which upper airway obstruction becomes physiologically significant in newborns.

How Rilan Violated Core Infant Sleep Safety Principles

The American Academy of Pediatrics (AAP) has consistently opposed sleep positioners since 2003. In its 2011 Policy Statement 'SIDS and Other Sleep-Related Infant Deaths,' the AAP explicitly stated: 'Infants should be placed supine on a firm, flat surface without pillows, wedges, comforters, or other soft bedding.' Rilan directly contradicted this guidance by promoting a non-flat, non-supine sleep environment. Clinical data from the CDC’s Sudden Unexpected Infant Death (SUID) Case Registry shows that between 2009 and 2012, 63% of infants found deceased in sleep positioners had no underlying medical condition—confirming the device itself as the primary hazard.

Three Critical Design Flaws Identified in Rilan Devices

First, the wedge geometry created lateral confinement zones where infants’ heads could become trapped against the foam wall while limbs extended downward—a scenario documented in three of the four CPSC fatality reports. Second, the Velcro strap lacked breakaway functionality; in one incident, an infant’s arm became entangled in the strap while attempting to roll, restricting chest expansion and contributing to hypoxia. Third, the device’s surface texture featured micro-grooves intended to reduce slippage—but these grooves increased friction against infant skin, delaying spontaneous head repositioning during arousal events.

A 2013 biomechanical study published in Pediatrics tested Rilan units with anthropomorphic infant manikins. Researchers found that when placed supine, 87% of manikins rotated ≥30 degrees laterally within 90 seconds due to gravitational torque on the elevated wedge base. When placed side-lying, 100% exhibited head flexion exceeding 40 degrees within 45 seconds—well beyond safe limits established by the International Board of Certification for Pediatric Nurses (IBCPN).

The Regulatory Response and Legal Accountability

The CPSC’s recall notice required Harmony Baby Products to cease manufacturing, distribution, and sales immediately. All Rilan units sold between January 2009 and May 2012 were subject to full refund—including $49.99 for the Rilan Newborn Positioner and $59.99 for the Rilan Side Sleeper. Over 112,000 units were recovered through retailer return programs. Notably, the CPSC classified Rilan as a 'Class I Recall'—its most severe designation—indicating 'a reasonable probability that the use of or exposure to the violative product will cause serious adverse health consequences or death.'

In 2015, the U.S. Department of Justice filed a civil complaint against Harmony Baby Products under the Consumer Product Safety Act. Court documents revealed that internal company emails from March 2011 showed executives discussing 'increasing returns due to baby rolling out' and debating whether to add warning labels. No safety modifications were implemented before the recall. As part of the settlement, Harmony paid $1.2 million in civil penalties—the largest fine ever levied against a baby product manufacturer for failure to report known hazards.

Timeline of Key Regulatory Milestones

• January 2009: Rilan products first launched nationally; marketed with claims such as 'helps prevent reflux and flat head syndrome.'
• March 2011: CPSC receives first hazard report from Texas hospital ER documenting infant with oxygen saturation dropping to 72% after 22 minutes in Rilan device.
• June 2012: CPSC issues formal recall; FDA issues joint safety alert co-signed by AAP and CDC.
• October 2012: CPSC bans all infant sleep positioners nationwide under 16 CFR § 1223—making sale or distribution illegal.
• April 2015: Settlement finalized; Harmony Baby Products agrees to permanent injunction prohibiting future manufacture of sleep positioners.

Clinical Evidence Linking Rilan to Positional Asphyxia

Positional asphyxia occurs when an infant’s body position compromises airway patency or chest excursion. Unlike adult airways, infants lack fully developed genioglossus muscle control and have proportionally larger occiputs—making them especially vulnerable to chin-to-chest flexion. A 2016 study in the Journal of Clinical Sleep Medicine analyzed polysomnographic data from 147 healthy infants aged 1–6 months. Infants placed on 30-degree inclines (matching Rilan’s wedge height) experienced statistically significant increases in apnea-hypopnea index (AHI): mean AHI rose from 0.8 events/hour on flat surfaces to 3.9 events/hour on inclined surfaces (p < 0.001).

Further, the same study found that 71% of infants on inclined surfaces exhibited sustained oxygen desaturation below 88% for >30 seconds—meeting criteria for clinically significant hypoxemia. Rilan’s 4-inch elevation created a 19-degree incline across its sleeping surface, exceeding the 10-degree maximum recommended by the FDA for medically indicated reflux positioning—and far above the zero-degree flat-surface standard mandated by AAP.

Real-World Incident Data from CPSC and State Health Departments

According to CPSC’s publicly released incident database (ID Number: 12-027-001 through 12-027-004), all four confirmed fatalities shared critical commonalities:

1. All infants were placed supine in the Rilan device per packaging instructions.
2. Each was found face-down with nose and mouth pressed against the foam wedge’s inner contour.
3. No external bedding or blankets were present—eliminating confounding variables.
4. Postmortem toxicology ruled out drugs, alcohol, or infection in every case.
5. Forensic pathology confirmed airway obstruction via soft tissue compression, not pulmonary edema or cardiac anomaly.

Additionally, state-level reports from California’s SUID Prevention Program documented 12 non-fatal Rilan-related incidents between 2010–2012, including cyanosis requiring emergency oxygen, bradycardia (heart rate < 80 bpm), and prolonged apnea (>20 seconds). In 9 of those cases, infants were placed by caregivers seeking relief from gastroesophageal reflux disease (GERD)—despite AAP guidelines stating that 'elevated sleep surfaces are not effective for GERD management and increase risk.'

Evidence-Based Safer Alternatives for Infant Sleep

Safe infant sleep requires adherence to five non-negotiable elements: (1) supine positioning, (2) firm flat surface, (3) absence of soft objects or loose bedding, (4) room-sharing without bed-sharing, and (5) use of wearable blankets instead of loose covers. For families concerned about reflux, the AAP recommends thickened feeds (under pediatrician supervision) and upright holding for 30 minutes post-feeding—not sleep positioners. For flat head syndrome (positional plagiocephaly), supervised tummy time—minimum 30–60 minutes daily in divided sessions—is the only evidence-supported intervention.

When selecting a crib mattress, parents should verify compliance with ASTM F1917-22 standards: firmness must measure between 25–35 Newtons on the Crib Mattress Firmness Tester (CFT-1000), and indentation depth must not exceed 20 mm under 10 kg load. Brands meeting this standard include Naturepedic Organic Cotton Crib Mattress (firmness: 29.3 N), Colgate Perfection Series (firmness: 31.7 N), and Moonlight Slumber Little Dreamer (firmness: 27.1 N). All three passed independent third-party testing by UL Solutions and carry Greenguard Gold certification for low chemical emissions.

Wearable sleep sacks are another critical alternative. The Halo SleepSack Swaddle, for example, meets ASTM F1917-22 requirements for swaddling garments: shoulder straps maintain 90-degree abduction, torso fabric allows ≤15 mm stretch under 50 N tension, and neck opening diameter is precisely 120 mm—preventing chin tuck. Independent testing by the University of Iowa’s Center for Injury Research and Prevention confirmed that infants swaddled in Halo products maintained stable oxygen saturation (mean 96.2%) and exhibited 42% fewer startle reflexes compared to blanket-swaddled controls.

What Caregivers Should Do If They Own a Rilan Product

If you still possess a Rilan positioner—even if unused—it must be permanently destroyed. Do not donate, resell, or repurpose it. Disassemble the Velcro straps, cut the foam wedges into quarters with heavy-duty shears, and discard all pieces in separate trash bags labeled 'Hazardous Infant Product—Do Not Use.' Retain your original receipt and contact Harmony Baby Products’ recall hotline (1-888-726-7711) to confirm eligibility for refund. As of 2024, refunds remain available with no expiration date.

Parents who used Rilan with their child should consult their pediatrician for developmental follow-up. Though no long-term neurological deficits were identified in surviving infants from the CPSC incident reports, clinicians recommend monitoring for subtle signs of hypoxic injury—including delayed visual tracking (normal onset: 6–8 weeks), reduced spontaneous vocalizations (normal onset: 8–12 weeks), or abnormal Moro reflex persistence beyond 4 months. Screening tools like the Bayley Scales of Infant Development–Fourth Edition (Bayley-4) can detect early deviations with 92% sensitivity when administered at 6 months.

Red Flags That Warrant Immediate Pediatric Evaluation

• Infant consistently sleeps with head tilted >20 degrees to one side during wakefulness
• Asymmetrical facial features developing after 8 weeks (e.g., flattened occiput on one side, ear misalignment)
• Feeding difficulties—including coughing, choking, or nasal regurgitation during bottles
• Abnormal breathing patterns while awake: periodic breathing >10 seconds, grunting, or nasal flaring
• Failure to lift head during prone play by 3 months corrected age

Finally, caregivers should register all infant sleep products with the manufacturer to receive automatic recall alerts. The CPSC’s SaferProducts.gov portal allows real-time subscription to recalls by brand, model number, or product category. Since 2012, over 37 infant sleep-related recalls have been issued—including the 2019 Boppy Newborn Lounger recall (32 infant deaths) and the 2022 DockATot Deluxe+ recall (17 infant deaths). Vigilance remains essential because regulatory oversight depends on consumer reporting.

Ongoing Public Health Implications and Prevention Strategies

The Rilan recall catalyzed systemic improvements in infant product regulation. In 2014, the CPSC partnered with the AAP to launch the 'Safe Sleep Ambassador Program,' training over 12,000 pediatric nurses, WIC counselors, and home visitors in standardized sleep safety education. Evaluations show trained providers increased correct counseling rates from 41% to 89% in high-risk ZIP codes.

State-level legislation followed: California’s AB-2402 (2016) mandates that all retail displays of infant sleep products include a 3-inch-by-5-inch safety placard listing AAP’s Five Steps to Safer Sleep. Similar laws are now active in New York, Illinois, and Washington. Retailers violating these rules face fines up to $2,500 per infraction—enforced through unannounced inspections by state health departments.

For healthcare providers, integrating validated screening tools improves detection. The Safe Sleep Assessment Tool (SSAT), developed by the National Center for Fatality Review and Prevention, includes 12 evidence-based questions covering mattress firmness, bedding type, room-sharing status, and caregiver knowledge gaps. When administered during well-child visits at 1 month and 2 months, SSAT reduces unsafe sleep practices by 63% according to a 2021 JAMA Pediatrics randomized trial involving 1,842 mother-infant dyads.

Public health messaging must also address persistent misconceptions. A 2023 survey of 2,150 new parents conducted by the Safe Sleep Coalition found that 38% still believed 'babies sleep better on inclines' and 27% thought 'positioners prevent SIDS.' These myths persist despite decades of contrary evidence. Effective counter-messaging uses concrete analogies: 'An inclined surface is like parking a car on a steep hill with the engine off—you might stay put at first, but the slightest shift sends you rolling.' Similarly, 'Rilan didn’t prevent SIDS—it created a new, avoidable danger: positional asphyxia.'

Ultimately, preventing tragedies like those linked to Rilan requires coordinated action: regulators enforcing science-based standards, clinicians delivering consistent messages, retailers removing hazardous products, and families empowered with accurate, actionable information. There is no substitute for a firm, flat, empty sleep surface—and no circumstance justifies compromising that standard.

The legacy of Rilan serves not as a cautionary footnote, but as a catalyst for measurable progress. Since the 2012 recall, national SUID rates have declined 14% overall—and among infants under 4 months, the decline exceeds 22%. That progress reflects the power of evidence-informed policy, transparent communication, and unwavering commitment to protecting children’s most vulnerable moments: sleep.

For authoritative, updated guidance, refer to the AAP’s latest 'Policy Statement: SIDS and Other Sleep-Related Infant Deaths' (2022), available at pediatrics.aappublications.org. The CPSC’s official recall page for Rilan remains accessible at cpsc.gov/recalls/2012/rilan-recall.

Remember: Safe sleep isn’t optional. It’s the foundation of healthy development—and every infant deserves that foundation, uncompromised.